KeyCorp Estimates Azenta’s Q1 Earnings (NASDAQ:AZTA)

Azenta, Inc. (NASDAQ:AZTA) – Research analysts at KeyCorp issued their Q1 2027 earnings per share estimates for Azenta in a note issued to investors on Wednesday, November 11th. KeyCorp analyst P. Knight forecasts that the company will post earnings per share of $0.15 for the quarter. KeyCorp also issued estimates for Azenta’s Q2 2027 earnings at $0.09 EPS, Q3 2027 earnings at $0.19 EPS, Q4 2027 earnings at $0.26 EPS, FY2027 earnings at $0.69 EPS and FY2028 earnings at $0.84 EPS.

Azenta (NASDAQ:AZTA) last released its earnings results on Tuesday, November 10th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.11 by $0.17. Azenta had a positive return on equity of 1.41% and a negative net margin of 26.86%. The firm had revenue of $167.09 million for the quarter, compared to analysts’ expectations of $160.16 million.

AZTA has been the topic of a number of other research reports. Jefferies Financial Group boosted their price objective on shares of Azenta from $44.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen downgraded shares of Azenta from a “buy” rating to a “hold” rating in a research report on Sunday, October 18th. Weiss Ratings raised shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 26th. Finally, Needham & Company LLC lifted their price target on shares of Azenta from $37.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $47.60.

Azenta Stock Down 10.3%

Shares of AZTA opened at $43.86 on Friday. The stock has a market capitalization of $1.92 billion, a P/E ratio of -12.12 and a beta of 1.47. Azenta has a twelve month low of $15.93 and a twelve month high of $50.06. The company has a 50 day moving average of $36.23 and a 200-day moving average of $28.53.

Institutional Investors Weigh In On Azenta

A number of institutional investors and hedge funds have recently made changes to their positions in AZTA. BlackRock Inc. bought a new position in shares of Azenta in the second quarter valued at $192,152,000. Front Street Capital Management Inc. bought a new stake in Azenta during the second quarter worth $33,212,000. American Capital Management Inc. bought a new stake in Azenta during the second quarter worth $27,089,000. Bank of America Corp DE acquired a new stake in Azenta in the second quarter valued at $17,058,000. Finally, Man Group plc acquired a new stake in Azenta in the second quarter valued at $9,402,000. Institutional investors own 99.08% of the company’s stock.

Azenta News Summary

Here’s some of the latest news about AZTA:

• Positive Sentiment: Needham raised its price target to $57 from $37 and maintained a Buy rating; Jefferies also kept a Buy rating while lifting its target to $52 from $44. Needham Adjusts Price Target on Azenta
• Negative Sentiment: After shares surged nearly 21% Wednesday and reached a new 52-week high, investors reportedly took profits, contributing to a retreat. This appears to reflect short-term selling after the rally rather than a reversal in the earnings news. Azenta dips as investors book profits
• Negative Sentiment: The Rosen Law Firm said it is investigating potential shareholder claims over allegations that Azenta may have issued materially misleading business information. The announcement describes an investigation, not a finding of wrongdoing. Rosen Law Firm investor notice

Azenta Company Profile

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.